Tag: Prescription Drugs
Findings Conflicted for Benefit of Tocilizumab in COVID-19
One trial shows reduction in mortality, but no evidence of efficacy seen in two additional trials
Dasatinib + Blinatumomab Active for Ph-Positive ALL in Adults
Complete remission, overall survival seen in 98, 95 percent of patients in phase 2 study
Tocilizumab Does Not Prevent Intubation, Death in COVID-19
Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients
CDC: 65.3 Percent of U.S. Women Currently Using Contraceptives
Female sterilization most common contraceptive method; use declined with higher education
Anti-VEGF Therapy May Aid Visual Acuity in Some nAMD Patients
Useful visual acuity preserved for about 20 percent of patients over their average remaining lifetime
Upadacitinib Tops Abatacept for RA Refractory to DMARDs
Superior for mean change in composite DAS28-CRP values and remission, but more adverse events seen
FDA Requiring Labeling Changes to NSAIDs Warning of Risks in Pregnancy
Labeling must indicate risks to unborn baby with NSAID use at 20 weeks of pregnancy or later
Ertugliflozin Noninferior for CV Outcomes in T2DM With ASCVD
Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events
Polypharmacy Common in Seniors With Heart Failure
With increasing number of medications, more rapid increase seen in number of noncardiovascular meds
NIH Launches Trial of Antibody Drugs Against COVID-19
The phase 2 trial will assess effectiveness of monoclonal antibodies in conjunction with remdesivir
